LUYE PHARMA: Submits New Drug Application in the U.S. for Its Antidepressant Drug LY03005
Luye Pharma Group has announced submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for LY03005, a new chemical drug for the treatment of major depressive disorder. It is also the second U.S. FDA NDA submission in the central nervous system (CNS) filed by the company. Read More »